GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » TELA Bio Inc (NAS:TELA) » Definitions » EBIT

TELA (TELA Bio) EBIT : $-36.17 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is TELA Bio EBIT?

TELA Bio's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2024 was $-9.03 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2024 was $-36.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TELA Bio's annualized ROC % for the quarter that ended in Sep. 2024 was -199.38%. TELA Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -247.80%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TELA Bio's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -25.61%.


TELA Bio EBIT Historical Data

The historical data trend for TELA Bio's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TELA Bio EBIT Chart

TELA Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial -18.82 -25.23 -29.68 -40.25 -41.44

TELA Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.62 -11.55 -4.33 -11.27 -9.03

Competitive Comparison of TELA Bio's EBIT

For the Medical Devices subindustry, TELA Bio's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TELA Bio's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, TELA Bio's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TELA Bio's EV-to-EBIT falls into.



TELA Bio EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-36.17 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TELA Bio  (NAS:TELA) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TELA Bio's annualized ROC % for the quarter that ended in Sep. 2024 is calculated as:

ROC % (Q: Sep. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2024 ) + Invested Capital (Q: Sep. 2024 ))/ count )
=-37.46 * ( 1 - 0% )/( (18.719 + 18.857)/ 2 )
=-37.46/18.788
=-199.38 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

TELA Bio's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2024  Q: Sep. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-36.112/( ( (4.2 + max(10.195, 0)) + (4.219 + max(10.532, 0)) )/ 2 )
=-36.112/( ( 14.395 + 14.751 )/ 2 )
=-36.112/14.573
=-247.80 %

where Working Capital is:

Working Capital(Q: Jun. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.097 + 13.372 + 2.144) - (14.989 + 0 + -0.571)
=10.195

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(11.222 + 13.6 + 2.009) - (16.858 + 0 + -0.559)
=10.532

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TELA Bio's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Sep. 2024 )
=-36.171/141.212
=-25.61 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TELA Bio EBIT Related Terms

Thank you for viewing the detailed overview of TELA Bio's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


TELA Bio Business Description

Traded in Other Exchanges
N/A
Address
1 Great Valley Parkway, Suite 24, Malvern, PA, USA, 19355
TELA Bio Inc is a United States-based medical technology company. The company is involved in developing and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. Its reinforced tissue matrices called OviTex improve the clinical outcomes and reduce costs of care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. The company's second portfolio of products, the OviTex PRS Reinforced Tissue Matrix, addresses unmet needs in plastic and reconstructive surgery.
Executives
Gregory A. Firestone officer: Chief Business Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Roberto Cuca officer: COO and CFO C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Paul Talmo officer: Chief Strategic Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Antony Koblish director, officer: Chief Executive Officer C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Iv Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Opaleye Management Inc. 10 percent owner ONE BOSTON PLACE, SUITE 2600, BOSTON MA 02108
Ew Healthcare Partners Fund 2-a, L.p. other: See footnotes 1 and 2 280 PARK AVENUE, 27TH FLOOR EAST, NEW YORK NY 10017
Quaker Bioventures Ii Lp 10 percent owner QUAKER BIOVENTURES, 2929 ARCH STREET, PHILADELPHIA PA 19104
Quaker Bioventures Capital Ii, L.p. 10 percent owner CIRA CENTER, 2929 ARCH STREET, PHILADELPHIA PA 19104
Lisa N Colleran director 0NE MILLENIUM WAY, BRANCHBURG NJ 08876
John Nosenzo director C/O BIOVENTUS INC., 4721 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703
Federica F. O'brien director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Kurt Azarbarzin director C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Douglas G Evans director 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355